ARCHIVES

XGEVA not Inferior to Zometa In 1,776-Patient Phase III Study

This article is from The Cancer Letter archive.

Vol. 34 No. 3 | March 25, 2011

Download PDF Visit The Full Archive

Related Articles

ACS: Decline in Death Rates Saved Over 1.3 Million Lives

January 10, 2014

Three-Quarters of P01 $$ Goes To Translational Grants, NCI Finds

October 2, 1992

Health Policy: Organ Procurement Should Cover Wider Areas, IOM Report Says

August 6, 1999

Excerpts Presented From Pepper Hearing

July 20, 1979

FDA Oncologic Drug Committee Agrees That “Kitty Fight” With NCI Should Be Negotiated

November 28, 1975

NCCN in Transition: New Strategy to Examine Role of Informatics, Revenue Sources and International Programs

June 15, 2012